exRNAdisease

General Information

Database ID:

exR0078806

RNA Name:

PGAM1

RNA Type:

mRNA

Chromosome:

chr10

Starnd:

Coordinate:

Start Site(bp):

97426191

End Site(bp):

97433444

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AASDHPPT	chr11	106075501	106098699	+
ABCB6	chr2	219209772	219218994	-
ABHD17C	chr15	80679684	80755621	+
ABI2	chr2	203328239	203447728	+
ABL2	chr1	179099330	179229684	-
AC007846.2	chr17	5772926	6080792	+
AC073082.1	chr2	48632291	48755724	-
AC091959.3	chr5	146203550	146339251	+
AC110275.1	chr8	43018424	43077334	+
AC139530.2	chr17	81703371	81720539	+
AC245033.1	chr15	82536788	82573194	-
ACACA	chr17	37084992	37406836	-
ACAT2	chr6	159762045	159779112	+
ACBD7	chr10	15075475	15088776	-
ACTB	chr7	5527148	5563784	-
ACTR1A	chr10	102461881	102502712	-
ACTR1B	chr2	97655939	97664044	-
ADA	chr20	44619522	44652233	-
ADAR	chr1	154582057	154628013	-
ADD2	chr2	70607618	70768225	-
AFAP1	chr4	7758714	7939926	-
AGBL5	chr2	27042364	27070622	+
AKT2	chr19	40230317	40285536	-
AL024498.2	chr6	10747794	10930423	+
AL157392.5	chr10	13610047	13655929	+
ALDH18A1	chr10	95605941	95656711	-
ALDOA	chr16	30064164	30070457	+

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-423-5p	chr17	30117095	30117117	+

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC009022.1	chr16	69976297	70065948	-
AC026461.1	chr16	56682470	56687807	+
AC245033.4	chr15	82533175	82540008	-
AL022311.1	chr22	37876148	37895563	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference